Kumar Ashutosh, Therrien Nicole L, Ogwuegbu John I, Lee Jun Soo, Wall Hilary K, Flack John M, Jackson Sandra L
Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA (A.K., N.L.T., J.I.O., J.S.L., H.K.W., S.L.J.).
The Bizzell Group, New Carrollton, MD (A.K.).
Hypertension. 2025 Jun;82(6):1106-1115. doi: 10.1161/HYPERTENSIONAHA.124.24316. Epub 2025 Apr 22.
Many medications can have blood pressure (BP)-elevating effects, which might negatively impact BP control among people with hypertension. This study examines trends in prescription fills for BP-elevating and antihypertensive medications, individually and concurrently, among US individuals.
Quarterly trends of individual and concurrent fills for BP-elevating and antihypertensive medications were reported using the nationwide sample from IQVIA's Total Patient Tracker database, covering 94% of all retail prescription fills in the United States. We identified 1387 products containing BP-elevating medications and 240 products containing antihypertensive medications. Percentage change from Q1/2017 and average quarterly percent change from the joinpoint regression were used to present trends overall and by sex and age group (0-17, 18-44, 45-64, 65-74, and ≥75 years).
From 2017 to 2023, fills remained stable for BP-elevating medications alone and increased for antihypertensive medications alone (9.5% increase; from 10.1% to 11.0%; <0.001). Concurrent fills for antihypertensive and BP-elevating medications increased by 15.9% (from 5.4% to 6.2%; <0.001). Fills for BP-elevating medications were higher among adult women compared with men; among women aged 18 to 44 years, this was primarily due to the use of combined oral contraceptives. In Q4/2023, fills for BP-elevating medications were most common among those aged 65 to 74 years (women=30.7%; men=20.4%).
These results provide the first nationwide trends in concurrent prescription fills for BP-elevating and antihypertensive medications, indicating an increasing trend. Our findings might inform clinician decision-making regarding medication selection for patients with hypertension.
许多药物可产生升高血压的作用，这可能对高血压患者的血压控制产生负面影响。本研究调查了美国个体单独及同时使用升高血压药物和抗高血压药物的处方配药趋势。
利用IQVIA全患者追踪数据库的全国样本报告升高血压药物和抗高血压药物单独及同时配药的季度趋势，该数据库涵盖美国94%的零售处方配药。我们识别出1387种含有升高血压药物的产品和240种含有抗高血压药物的产品。采用2017年第一季度以来的百分比变化以及连接点回归得出的季度平均百分比变化来呈现总体趋势以及按性别和年龄组（0 - 17岁、18 - 44岁、45 - 64岁、65 - 74岁和≥75岁）划分的趋势。
2017年至2023年，单独使用升高血压药物的配药量保持稳定，而单独使用抗高血压药物的配药量有所增加（增加9.5%；从10.1%增至11.0%；<0.001）。抗高血压药物与升高血压药物同时使用的配药量增加了15.9%（从5.4%增至6.2%；<0.001）。成年女性使用升高血压药物的配药量高于男性；在18至44岁的女性中，这主要是由于使用复方口服避孕药。在2023年第四季度，65至74岁人群中使用升高血压药物的配药最为常见（女性 = 30.7%；男性 = 20.4%）。
这些结果首次呈现了全国范围内同时使用升高血压药物和抗高血压药物的处方配药趋势，显示出上升趋势。我们的研究结果可能为临床医生为高血压患者选择药物提供参考。
